Elena Nasonova

Dr. Elena Nasonova

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2006 in Radiation and Environmental Biophysics
Verified
Journal Article
Closed access
PDF file
ENElena Nasonova
Elena Nasonova
NSN. L. Shmakova
N. L. Shmakova
OKO. V. Komova
O. V. Komova
LML. A. Mel’Nikova
L. A. Mel’Nikova
TFT. A. Fadeeva
T. A. Fadeeva
SRS. Ritter
S. Ritter

NPNerea Paz
Nerea Paz
CHCarola Hartel
Carola Hartel
ENElena Nasonova
Elena Nasonova
ADAnna-Jasmina Donaubauer
Anna-Jasmina Donaubauer
Benjamin FreyBenjamin Frey
Benjamin Frey
SRSylvia Ritter
Sylvia Ritter
In the present exploratory study, we aim to elucidate the action of radon in vivo and to assess the possible health risks. Chromosome aberrations were analyzed in lymphocytes of two patients (P1, P2) undergoing radon spa therapy in Bad Steben (Germany). Both patients, suffering from painful chronic degenerative disorders of the spine and joints, received nine baths (1.2 kBq/L at 34 °C) over a 3-week period. Chromosome aberrations were analyzed before and 6, 12 and 30 weeks after the start of therapy using the high-resolution multiplex fluorescence in situ hybridization (mFISH) technique. For comparison, the lymphocytes from two healthy donors (HD1, HD2) were examined. P1 had a higher baseline aberration frequency than P2 and both healthy donors (5.3 ± 1.3 vs. 2.0 ± 0.8, 1.4 ± 0.3 and 1.1 ± 0.1 aberrations/100 analyzed metaphases, respectively). Complex aberrations, biomarkers of densely ionizing radiation, were found in P1, P2 and HD1. Neither the aberration frequency nor the fraction of complex aberrations increased after radon spa treatment, i.e., based on biological dosimetry, no increased health risk was found. It is worth noting that a detailed breakpoint analysis revealed potentially clonal aberrations in both patients. Altogether, our data show pronounced inter-individual differences with respect to the number and types of aberrations, complicating the risk analysis of low doses such as those received during radon therapy.

Verified
Journal Article
Open access
PDF file
IKIgor Khvostunov
Igor Khvostunov
ENElena Nasonova
Elena Nasonova
VKValeriy Krylov
Valeriy Krylov
АRАндрей Алексеевич Andrei Rodichev
Андрей Алексеевич Andrei Rodichev
TKTatiana Kochetova
Tatiana Kochetova
AKAndrei Kaprin
Andrei Kaprin
The risk of toxicity attributable to radioiodine therapy (RIT) remains a subject of ongoing research, with a whole-body dose of 2 Gy proposed as a safe limit. This article evaluates the RIT-induced cytogenetic damage in two rare differentiated thyroid cancer (DTC) cases, including the first follow-up study of a pediatric DTC patient. Chromosome damage in the patient’s peripheral blood lymphocytes (PBL) was examined using conventional metaphase assay, painting of chromosomes 2, 4, and 12 (FISH), and multiplex fluorescence in situ hybridization (mFISH). Patient 1 (female, 1.6 y.o.) received four RIT courses over 1.1 years. Patient 2 (female, 49 y.o.) received 12 courses over 6.4 years, the last two of which were examined. Blood samples were collected before and 3–4 days after the treatment. Chromosome aberrations (CA) analyzed by conventional and FISH methods were converted to a whole-body dose accounting for the dose rate effect. The mFISH method showed an increase in total aberrant cell frequency following each RIT course, while cells carrying unstable aberrations predominated in the yield. The proportion of cells containing stable CA associated with long-term cytogenetic risk remained mostly unchanged during follow-up for both patients. A one-time administration of RIT was safe, as the threshold of 2 Gy for the whole-body dose was not exceeded. The risk of side effects projected from RIT-attributable cytogenetic damage was low, suggesting a good long-term prognosis. In rare cases, such as the ones reviewed in this study, individual planning based on cytogenetic biodosimetry is strongly recommended.

20 July 2002
Verified
Journal Article
Closed access
NSN L Shmakova
N L Shmakova
TFT A Fadeeva
T A Fadeeva
ENElena Nasonova
Elena Nasonova
EKE A Krasavin
E A Krasavin
ARA V Rzianina
A V Rzianina

6 October 2006
Verified
Journal Article
Closed access
NSN L Shmakova
N L Shmakova
ENElena Nasonova
Elena Nasonova
EKE A Krasavin
E A Krasavin
OKO V Komova
O V Komova
LML A Mel'Nikova
L A Mel'Nikova
TFT A Fadeeva
T A Fadeeva

Verified
Journal Article
Open access
PDF file
IKIgor Khvostunov
Igor Khvostunov
ENElena Nasonova
Elena Nasonova
PLPavel Lobachevsky
Pavel Lobachevsky
VKValeriy Krylov
Valeriy Krylov
ASAndrei Shurinov
Andrei Shurinov
AKAndrei Kaprin
Andrei Kaprin
This study investigated cytogenetic damage in peripheral blood lymphocytes of 10 differentiated thyroid cancer patients who received multiple 131I radioiodine (RAI) treatments following total thyroidectomy. Blood samples were collected before the RAI therapy course and 2–3 days after the course for a few selected courses (from 1 to 3) for each patient. The cumulative average number of chromosome aberrations (CAs) per cell and its increment due to a selected RAI course were evaluated using the multiplex fluorescence in situ hybridization method (mFISH). An increase in the number of CAs was observed with the accumulation of RAI activity. The yield of these CAs per unit of accumulated RAI activity was, however, approximately three-fold lower than the respective yield for the incremented number of CAs in a selected course, thus demonstrating the elimination of CAs and/or aberrant cells with time. Biological dosimetry was performed based on the number of all types of CAs and in vitro mFISH calibration curves. With an average administered RAI activity of 3.40 ± 0.39 GBq, the average absorbed blood dose was 0.61 Gy (0.31–0.89:95% CI). Our results demonstrate that one-time administration of such activities of RAI was safe, since the commonly accepted threshold of 2 Gy for the blood dose was not exceeded.